Syndax Pharmaceuticals (SNDX) Retained Earnings (2016 - 2025)
Historic Retained Earnings for Syndax Pharmaceuticals (SNDX) over the last 11 years, with Q3 2025 value amounting to -$1.4 billion.
- Syndax Pharmaceuticals' Retained Earnings fell 2764.69% to -$1.4 billion in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.4 billion, marking a year-over-year decrease of 2764.69%. This contributed to the annual value of -$1.2 billion for FY2024, which is 3532.34% down from last year.
- As of Q3 2025, Syndax Pharmaceuticals' Retained Earnings stood at -$1.4 billion, which was down 2764.69% from -$1.4 billion recorded in Q2 2025.
- Syndax Pharmaceuticals' Retained Earnings' 5-year high stood at -$543.7 million during Q4 2021, with a 5-year trough of -$1.4 billion in Q3 2025.
- Moreover, its 5-year median value for Retained Earnings was -$778.8 million (2023), whereas its average is -$877.8 million.
- Per our database at Business Quant, Syndax Pharmaceuticals' Retained Earnings surged by 438.35% in 2021 and then crashed by 3579.38% in 2024.
- Quarter analysis of 5 years shows Syndax Pharmaceuticals' Retained Earnings stood at -$543.7 million in 2021, then dropped by 27.47% to -$693.0 million in 2022, then tumbled by 30.21% to -$902.4 million in 2023, then tumbled by 35.32% to -$1.2 billion in 2024, then decreased by 17.8% to -$1.4 billion in 2025.
- Its Retained Earnings was -$1.4 billion in Q3 2025, compared to -$1.4 billion in Q2 2025 and -$1.3 billion in Q1 2025.